{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T15:53:17Z","timestamp":1777737197517,"version":"3.51.4"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[2014,10,21]],"date-time":"2014-10-21T00:00:00Z","timestamp":1413849600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s12016-014-8456-5","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T05:53:05Z","timestamp":1413784385000},"page":"263-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["New Therapies for Primary Biliary Cirrhosis"],"prefix":"10.1007","volume":"48","author":[{"given":"Annarosa","family":"Floreani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Franceschet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Perini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Cazzagon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"Bowlus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,21]]},"reference":[{"key":"8456_CR1","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","volume":"377","author":"C Selmi","year":"2011","unstructured":"Selmi C, Bowlus CL, Gershwin ME, Coppel RL (2011) Primary biliary cirrhosis. Lancet 377:1600\u20131609","journal-title":"Lancet"},{"key":"8456_CR2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12016-012-8324-0","volume":"43","author":"K Kawata","year":"2012","unstructured":"Kawata K, Kobayashi Y, Gershwin ME, Bowlus CL (2012) The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol 43:230\u2013241","journal-title":"Clin Rev Allergy Immunol"},{"key":"8456_CR3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-2005-916321","volume":"25","author":"P Invernizzi","year":"2005","unstructured":"Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J (2005) Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 25:298\u2013310","journal-title":"Semin Liver Dis"},{"key":"8456_CR4","doi-asserted-by":"crossref","unstructured":"Norman GL, Yang CY, Ostendorff HP et al. (2014) Anti-Kelch-like 12 and anti-Hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int, in press","DOI":"10.1111\/liv.12690"},{"key":"8456_CR5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.autrev.2014.01.041","volume":"13","author":"CL Bowlus","year":"2014","unstructured":"Bowlus CL, Gershwin ME (2014) The diagnosis of primary biliary cirrhosis. Autoimmun Rev 13:441\u2013444","journal-title":"Autoimmun Rev"},{"key":"8456_CR6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1478-3231.2010.02366.x","volume":"31","author":"A Floreani","year":"2011","unstructured":"Floreani A, Caroli D, Variola A, Rizzotto ER, Antoniazzi S, Chiaramonte M, Cazzagon N, Brombin C, Salmaso L, Baldo V (2011) A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int 31:361\u2013368","journal-title":"Liver Int"},{"key":"8456_CR7","doi-asserted-by":"crossref","unstructured":"Quarneti C, Muratori P, Lalanne C, Fabbri A, Menichella R, Granito A, Masi C, Lenzi M, Cassani F, Pappas G, Muratori L (2014) Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int, in press","DOI":"10.1111\/liv.12560"},{"key":"8456_CR8","doi-asserted-by":"crossref","unstructured":"Floreani A, Franceschet I, Cazzagon N, Spinazz\u00e8 A, Buja A, Furlan P, Baldo V, Gershwin ME (2014) Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clinic Rev Allerg Immunol, in press","DOI":"10.1007\/s12016-014-8427-x"},{"key":"8456_CR9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the, L","year":"2009","unstructured":"European Association for the Study of the, L (2009) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51:237\u2013267","journal-title":"J Hepatol"},{"key":"8456_CR10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (2009) Primary biliary cirrhosis. Hepatology 50:291\u2013308","journal-title":"Hepatology"},{"key":"8456_CR11","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1751-2980.2010.00427.x","volume":"11","author":"G Paumgartner","year":"2010","unstructured":"Paumgartner G (2010) Pharmacotherapy of cholestatic liver diseases. J Digest Dis 11:1095\u20131106","journal-title":"J Digest Dis"},{"key":"8456_CR12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.23783","volume":"52","author":"A Lleo","year":"2010","unstructured":"Lleo A, Bowlus CL, Yang GX et al (2010) Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology 52:987\u2013998","journal-title":"Hepatology"},{"key":"8456_CR13","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1002\/ijc.21729","volume":"118","author":"C Loddenkemper","year":"2006","unstructured":"Loddenkemper C, Keller S, Hanski ML et al (2006) Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid. Int J Cancer 118:2750\u20132757","journal-title":"Int J Cancer"},{"key":"8456_CR14","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","volume":"106","author":"KD Lindor","year":"1994","unstructured":"Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM et al (1994) Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106:1284\u20131290","journal-title":"Gastroenterology"},{"key":"8456_CR15","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","volume":"324","author":"RE Poupon","year":"1991","unstructured":"Poupon RE, Balkau B, Eschwege E, Poupon R (1991) A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC study group. N Engl J Med 324:1548\u20131554","journal-title":"N Engl J Med"},{"key":"8456_CR16","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","volume":"19","author":"EJ Heathcote","year":"1994","unstructured":"Heathcote EJ, Cauch-Dudek K, Walker V et al (1994) The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19:1149\u20131156","journal-title":"Hepatology"},{"key":"8456_CR17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","volume":"29","author":"P Angulo","year":"1999","unstructured":"Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD (1999) Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 29:644\u2013647","journal-title":"Hepatology"},{"key":"8456_CR18","first-page":"759","volume":"22","author":"B Combes","year":"1995","unstructured":"Combes B, Carithers RL, Maddrey WC et al (1995) A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22:759\u2013766","journal-title":"Hepatology"},{"key":"8456_CR19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/00365529709000190","volume":"32","author":"LS Eriksson","year":"1997","unstructured":"Eriksson LS, Olsson R, Glauman H et al (1997) Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. Scand J Gastroenterol 32:179\u2013186","journal-title":"Scand J Gastroenterol"},{"key":"8456_CR20","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1572-0241.2002.05923.x","volume":"97","author":"GV Papatheodoridis","year":"2002","unstructured":"Papatheodoridis GV, Hadziyannis ES, Deutsch M, Hadziyannis SJ (2002) Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. Am J Gastroenterol 97:2063\u20132070","journal-title":"Am J Gastroenterol"},{"key":"8456_CR21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","volume":"32","author":"A Pares","year":"2000","unstructured":"Pares A, Caballeria L, Rodes J et al (2000) Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 32:561\u2013566","journal-title":"J Hepatol"},{"key":"8456_CR22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","volume":"128","author":"C Corpechot","year":"2005","unstructured":"Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R (2005) The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128:297\u2013303","journal-title":"Gastroenterology"},{"key":"8456_CR23","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","volume":"102","author":"Y Gong","year":"2007","unstructured":"Gong Y, Huang ZB, Christensen E, Gluud C (2007) Ursodeoxycholic acid for primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 102:1799\u20131807","journal-title":"Am J Gastroenterol"},{"key":"8456_CR24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","volume":"354","author":"J Goulis","year":"1999","unstructured":"Goulis J, Leandro G, Burroughs AK (1999) Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354:1053\u20131060","journal-title":"Lancet"},{"key":"8456_CR25","first-page":"1","volume":"12","author":"JS Rudic","year":"2012","unstructured":"Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C (2012) Ursodeoxycholic acid for primary biliary cirrhosis (review). Cochrane Libr 12:1\u201375","journal-title":"Cochrane Libr"},{"key":"8456_CR26","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N et al (2008) Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48:871\u2013877","journal-title":"Hepatology"},{"key":"8456_CR27","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","volume":"136","author":"EM Kuiper","year":"2009","unstructured":"Kuiper EM, Hansen BE, de Vries RA et al (2009) Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 136:1281\u20131287","journal-title":"Gastroenterology"},{"key":"8456_CR28","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","volume":"105","author":"T Kumagi","year":"2010","unstructured":"Kumagi T, Guindi M, Fischer SE et al (2010) Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 105:2186\u20132194","journal-title":"Am J Gastroenterol"},{"key":"8456_CR29","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","volume":"130","author":"A Pares","year":"2006","unstructured":"Pares A, Caballeria L, Rodes J (2006) Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 130:715\u2013720","journal-title":"Gastroenterology"},{"key":"8456_CR30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","volume":"144","author":"M Carbone","year":"2013","unstructured":"Carbone M, Mells GF, Pells G et al (2013) Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 144:560\u2013569","journal-title":"Gastroenterology"},{"key":"8456_CR31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/s-0034-1383733","volume":"34","author":"A Pares","year":"2014","unstructured":"Pares A (2014) Old and novel therapies for primary biliary cirrhosis. Semin Liver Dis 34:341\u2013351","journal-title":"Semin Liver Dis"},{"key":"8456_CR32","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","volume":"117","author":"M Leuschner","year":"1999","unstructured":"Leuschner M, Maier KP, Schlichting J (1999) Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117:918\u2013925","journal-title":"Gastroenterology"},{"key":"8456_CR33","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","volume":"41","author":"H Rautiainen","year":"2005","unstructured":"Rautiainen H, Kirkkainen P, Karvonen A-L, Nurmi H, Pikkarainen P, Nuutinen H, Farkkila M (2005) Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 41:747\u2013752","journal-title":"Hepatology"},{"key":"8456_CR34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","volume":"31","author":"P Angulo","year":"2000","unstructured":"Angulo P, Jorgensen RA, Keack JC, Dickson ER, Smith C, Lindor KD (2000) Oral budesonide in the treatment of patients with primary biliary cirrhosis with suboptimal response to ursodeoxycholic acid. Hepatology 31:318\u2013323","journal-title":"Hepatology"},{"key":"8456_CR35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.gcb.2010.02.004","volume":"34","author":"N Rabahi","year":"2010","unstructured":"Rabahi N, Chretien Y, Gaouar F et al (2010) Triple therapy with ursodeoxycholic acid. Budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol 34:283\u2013287","journal-title":"Gastroenterol Clin Biol"},{"key":"8456_CR36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","volume":"38","author":"W Hempfling","year":"2003","unstructured":"Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T (2003) Pharmacokinetics and pharmacodynamics action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38:196\u2013202","journal-title":"Hepatology"},{"key":"8456_CR37","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","volume":"45","author":"R Pellicciari","year":"2002","unstructured":"Pellicciari R, Fiorucci S, Camaioni E et al (2002) 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45:3569\u20133572","journal-title":"J Med Chem"},{"key":"8456_CR38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpcardio0558","volume":"3","author":"U Beuers","year":"2006","unstructured":"Beuers U (2006) Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract 3:318\u2013328","journal-title":"Nat Clin Pract"},{"key":"8456_CR39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","volume":"60","author":"RM Gadaleta","year":"2011","unstructured":"Gadaleta RM, van Erpecum KJ, Oldenburg B et al (2011) Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60:463\u2013472","journal-title":"Gut"},{"key":"8456_CR40","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","volume":"59","author":"L Verbeke","year":"2014","unstructured":"Verbeke L, Farre R, Trebicka J et al (2014) Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59:2286\u20132298","journal-title":"Hepatology"},{"key":"8456_CR41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2013.11.057","volume":"443","author":"W Wu","year":"2014","unstructured":"Wu W, Zhu B, Peng X, Zhou M, Jia D, Gu J (2014) Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun 443:68\u201373","journal-title":"Biochem Biophys Res Commun"},{"key":"8456_CR42","first-page":"357A","volume":"52","author":"A Mason","year":"2010","unstructured":"Mason A, Luketic V, Lindor K et al (2010) Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of obeticholic acid (INT-747) to ursodeoxycholic acid. Hepatology 52:357A","journal-title":"Hepatology"},{"key":"8456_CR43","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0168-8278(11)60030-5","volume":"54","author":"KV Kowdley","year":"2011","unstructured":"Kowdley KV, Jones D, Luketic V et al (2011) An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol 54:S13","journal-title":"J Hepatol"},{"key":"8456_CR44","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/S0168-8278(14)61463-X","volume":"60","author":"F Nevens","year":"2014","unstructured":"Nevens F, Andreone P, Mazzella G et al (2014) The first primary biliary cirrhosis phase 3 trial in two decades\u2014an international study of the FXR agonist obeticholic acid in PBC patients. J Hepatol 60:S525\u2013S526","journal-title":"J Hepatol"},{"key":"8456_CR45","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","volume":"43","author":"TM Willson","year":"2000","unstructured":"Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527\u2013550","journal-title":"J Med Chem"},{"key":"8456_CR46","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.26894","volume":"59","author":"NS Ghonem","year":"2014","unstructured":"Ghonem NS, Ananthanarayanan M, Soroka CJ, Boyer JL (2014) Peroxisome proliferator-activated receptor \u03b1 activates human multidrug resistance transporter 3\/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. Hepatology 59:1030\u20131042","journal-title":"Hepatology"},{"key":"8456_CR47","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","volume":"57","author":"A Honda","year":"2013","unstructured":"Honda A, Ikegami T, Nakamuta M et al (2013) Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 57:1931\u20131941","journal-title":"Hepatology"},{"key":"8456_CR48","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M004045200","volume":"275","author":"P Delerive","year":"2000","unstructured":"Delerive P, Gervois P, Fruchart JC, Staels B (2000) Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 275:36703\u201336707","journal-title":"J Biol Chem"},{"key":"8456_CR49","doi-asserted-by":"crossref","first-page":"35715","DOI":"10.1074\/jbc.M006577200","volume":"275","author":"T Miyahara","year":"2000","unstructured":"Miyahara T, Schrum L, Rippe R et al (2000) Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275:35715\u201335722","journal-title":"J Biol Chem"},{"key":"8456_CR50","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0026-0495(93)90056-T","volume":"42","author":"AP Day","year":"1993","unstructured":"Day AP, Feher MD, Chopra R, Mayne PD (1993) The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism 42:839\u201342","journal-title":"Metabolism"},{"key":"8456_CR51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","volume":"16","author":"S Iwasaki","year":"1999","unstructured":"Iwasaki S, Tsuda K, Ueta H et al (1999) Bezafibrate may have a beneficial effect in precirrhotic primary biliary cirrhosis. Hepatol Res 16:12\u201318","journal-title":"Hepatol Res"},{"key":"8456_CR52","first-page":"1518","volume":"47","author":"S Miyaguchi","year":"2000","unstructured":"Miyaguchi S, Ebinuma H, Imaeda H, Nitta Y, Watanabe T, Saito H, Ishii H (2000) A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology 47:1518\u20131521","journal-title":"Hepatogastroenterology"},{"key":"8456_CR53","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","volume":"95","author":"S Nakai","year":"2000","unstructured":"Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M (2000) Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 95:326\u2013327","journal-title":"Am J Gastroenterol"},{"key":"8456_CR54","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","volume":"95","author":"T Kurihara","year":"2000","unstructured":"Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K, Hashimoto E (2000) Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 95:2990\u20132992","journal-title":"Am J Gastroenterol"},{"key":"8456_CR55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0676.2001.021003223.x","volume":"21","author":"K Ohmoto","year":"2001","unstructured":"Ohmoto K, Mitsui Y, Yamamoto S (2001) Effect of bezafibrate in primary biliary cirrhosis: a pilot study. Liver 21:223\u2013224","journal-title":"Liver"},{"key":"8456_CR56","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1572-0241.2002.05645.x","volume":"97","author":"K Yano","year":"2002","unstructured":"Yano K, Kato H, Morita S, Takahara O, Ishibashi H, Furukawa R (2002) Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol 97:1075\u20131077","journal-title":"Am J Gastroenterol"},{"key":"8456_CR57","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","volume":"38","author":"T Kanda","year":"2003","unstructured":"Kanda T, Yokosuka O, Imazeki F, Saisho H (2003) Bezafibrate treatment a new medical approach for PBC patients? J Gastroenterol 38:573\u2013578","journal-title":"J Gastroenterol"},{"key":"8456_CR58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","volume":"29","author":"J Itakura","year":"2004","unstructured":"Itakura J, Izumi N, Nishimura Y et al (2004) Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res 29:216\u2013222","journal-title":"Hepatol Res"},{"key":"8456_CR59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00535-004-1518-3","volume":"40","author":"SMF Akbar","year":"2005","unstructured":"Akbar SMF, Furukawa S, Nakanishi S, Abe M, Horiike N, Onji M (2005) Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J Gastroenterol 40:157\u2013163","journal-title":"J Gastroenterol"},{"key":"8456_CR60","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00535-004-1583-7","volume":"40","author":"M Nakamuta","year":"2005","unstructured":"Nakamuta M, Enjoji M, Kotoh K, Shimohashi N, Tanabe Y (2005) Long-term fibrate treatment for PBC. J Gastroenterol 40:546\u2013547","journal-title":"J Gastroenterol"},{"key":"8456_CR61","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00535-006-1778-1","volume":"41","author":"K Ohmoto","year":"2006","unstructured":"Ohmoto K, Yoshioka N, Yamamoto S (2006) Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis. J Gastroenterol 41:502\u2013503","journal-title":"J Gastroenterol"},{"key":"8456_CR62","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","volume":"41","author":"R Kita","year":"2006","unstructured":"Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N (2006) Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 41:686\u2013692","journal-title":"J Gastroenterol"},{"key":"8456_CR63","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.1111\/j.1872-034X.2007.00232.x","volume":"37","author":"S Iwasaki","year":"2007","unstructured":"Iwasaki S, Akisawa N, Saibara T, Onishi S (2007) Fibrate for treatment of primary biliary cirrhosis. Hepatol Res 37:S515\u2013S517","journal-title":"Hepatol Res"},{"key":"8456_CR64","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","volume":"38","author":"S Iwasaki","year":"2008","unstructured":"Iwasaki S, Ohira H, Nishiguchi S et al (2008) The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multi center study. Hepatol Res 38:557\u2013564","journal-title":"Hepatol Res"},{"key":"8456_CR65","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","volume":"44","author":"R Hazzan","year":"2010","unstructured":"Hazzan R, Tur-Kaspa R (2010) Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 44:371\u2013373","journal-title":"J Clin Gastroenterol"},{"key":"8456_CR66","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1440-1746.2011.06737.x","volume":"26","author":"Y Takeuchi","year":"2011","unstructured":"Takeuchi Y, Ikeda F, Fujioka S-I et al (2011) Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol 26:1395\u20131401","journal-title":"J Gastroenterol Hepatol"},{"key":"8456_CR67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","volume":"34","author":"S Lens","year":"2014","unstructured":"Lens S, Leoz M, Nazal L, Bruguera M, Par\u00e9s A (2014) Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 34:197\u2013203","journal-title":"Liver Int"},{"key":"8456_CR68","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","volume":"97","author":"H Ohira","year":"2002","unstructured":"Ohira H, Sato Y, Ueno T, Sata M (2002) Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 97:2147\u20132149","journal-title":"Am J Gastroenterol"},{"key":"8456_CR69","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","volume":"10","author":"K Dohmen","year":"2004","unstructured":"Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K (2004) Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 10:894\u2013898","journal-title":"World J Gastroenterol"},{"key":"8456_CR70","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hep.22670","volume":"49","author":"LJ Walker","year":"2009","unstructured":"Walker LJ, Newton J, Jones DE, Bassendine MF (2009) Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 49:337\u2013338","journal-title":"Hepatology"},{"key":"8456_CR71","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","volume":"4","author":"EN Liberopoulos","year":"2010","unstructured":"Liberopoulos EN, Florentin M, Elisaf MS, Mikhailidis DP, Tsianos E (2010) Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J 4:120\u2013126","journal-title":"Open Cardiovasc Med J"},{"key":"8456_CR72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","volume":"33","author":"C Levy","year":"2011","unstructured":"Levy C, Peter JA, Nelson DR et al (2011) Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 33:235\u2013242","journal-title":"Aliment Pharmacol Ther"},{"key":"8456_CR73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","volume":"13","author":"XF Han","year":"2012","unstructured":"Han XF, Wang QX, Liu Y, You ZR, Bian ZL, de Qiu K, Ma X (2012) Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis 13:219\u2013224","journal-title":"J Dig Dis"},{"key":"8456_CR74","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.blre.2013.07.002","volume":"27","author":"I Avivi","year":"2013","unstructured":"Avivi I, Stroopinsky D, Katz T (2013) Anti-CD20 monoclonal antibodies: beyond B cells. Blood Rev 27:217\u2013223","journal-title":"Blood Rev"},{"key":"8456_CR75","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.23238","volume":"50","author":"Y Moritoki","year":"2009","unstructured":"Moritoki Y, Lian ZX, Lindor K et al (2009) B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology 50:1893\u20131903","journal-title":"Hepatology"},{"key":"8456_CR76","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","volume":"55","author":"M Tsuda","year":"2012","unstructured":"Tsuda M, Moritoki Y, Lian ZX et al (2012) Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 55:512\u2013521","journal-title":"Hepatology"},{"key":"8456_CR77","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","volume":"108","author":"RP Myers","year":"2013","unstructured":"Myers RP, Swain MG, Lee SS, Shaheen AA, Burak KW (2013) B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol 108:933\u2013941","journal-title":"Am J Gastroenterol"},{"key":"8456_CR78","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000351173","volume":"7","author":"K Tajiri","year":"2013","unstructured":"Tajiri K, Tsuneyama K, Miyazono T, Kawai K, Minemura M, Sugiyama T (2013) A case of primary biliary cirrhosis that progressed rapidly after treatment involving rituximab. Case Rep Gastroenterol 7:195\u2013201","journal-title":"Case Rep Gastroenterol"},{"key":"8456_CR79","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s004280050077","volume":"431","author":"HP Dienes","year":"1997","unstructured":"Dienes HP, Lohse AW, Gerken G, Schirmacher P, Gallati H, Lohr HF, Meyer zum B\u00fcschenfelde KH (1997) Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. Virchows Arch 431:119\u2013122","journal-title":"Virchows Arch"},{"key":"8456_CR80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jbspin.2007.03.003","volume":"75","author":"A Spadaro","year":"2008","unstructured":"Spadaro A, Scrivo R, Riccieri V, Valesini G (2008) Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine 75:87\u201389","journal-title":"Joint Bone Spine"},{"key":"8456_CR81","first-page":"101","volume":"6","author":"JK Triantafillidis","year":"2013","unstructured":"Triantafillidis JK, Durakis S, Merikas E et al (2013) Crohn\u2019s disease of the small bowel, complicated by primary biliary cirrhosis, Hashimoto thyroiditis, and Raynaud\u2019s phenomenon: favorable response of all disorders to adalimumab treatment. Gastroenterol Hepatol Bed Bench 6:101\u2013105","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"8456_CR82","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","volume":"360","author":"GM Hirschfield","year":"2009","unstructured":"Hirschfield GM, Liu X, Xu C et al (2009) Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 360:2544\u20132555","journal-title":"N Engl J Med"},{"key":"8456_CR83","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ng.627","volume":"42","author":"X Liu","year":"2010","unstructured":"Liu X, Invernizzi P, Lu Y et al (2010) Genome-wide meta-analyses identifies three loci associated with primary biliary cirrhosis. Nat Genet 42:658\u2013660","journal-title":"Nat Genet"},{"key":"8456_CR84","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.789","volume":"43","author":"GF Mells","year":"2011","unstructured":"Mells GF, Floyd JA, Morley KI et al (2011) Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 43:329\u2013332","journal-title":"Nat Genet"},{"key":"8456_CR85","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.23132","volume":"50","author":"K Yoshida","year":"2009","unstructured":"Yoshida K, Yang GX, Zhang W et al (2009) Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology 50:1494\u20131500","journal-title":"Hepatology"},{"key":"8456_CR86","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jhep.2011.05.040","volume":"56","author":"A Lleo","year":"2012","unstructured":"Lleo A, Gershwin ME, Mantovani A, Invernizzi P (2012) Towards common denominators in primary biliary cirrhosis: the role of IL-12. J Hepatol 56:731\u2013733","journal-title":"J Hepatol"},{"key":"8456_CR87","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2008.12.002","volume":"8","author":"EY Lee","year":"2009","unstructured":"Lee EY, Lee ZH, Song YW (2009) CXCL10 and autoimmune diseases. Autoimmun Rev 8:379\u2013383","journal-title":"Autoimmun Rev"},{"key":"8456_CR88","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaut.2005.08.009","volume":"25","author":"YH Chuang","year":"2005","unstructured":"Chuang YH, Lian ZX, Cheng CM et al (2005) Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives. J Autoimmun 25:126\u2013132","journal-title":"J Autoimmun"},{"key":"8456_CR89","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2249.2001.01391.x","volume":"123","author":"K Nishioji","year":"2001","unstructured":"Nishioji K, Okanoue T, Itoh Y et al (2001) Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 123:271\u2013279","journal-title":"Clin Exp Immunol"},{"key":"8456_CR90","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gutjnl-2012-303424","volume":"63","author":"L Mayer","year":"2014","unstructured":"Mayer L, Sandborn WJ, Stepanov Y et al (2014) Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut 63:442\u2013450","journal-title":"Gut"},{"key":"8456_CR91","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1172\/JCI4213","volume":"102","author":"S Shimoda","year":"1998","unstructured":"Shimoda S, Van de Water J, Ansari A et al (1998) Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 102:1831\u20131840","journal-title":"J Clin Invest"},{"key":"8456_CR92","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1053\/gast.2002.36020","volume":"123","author":"H Kita","year":"2002","unstructured":"Kita H, Naidenko OV, Kronenberg M et al (2002) Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123:1031\u20131043","journal-title":"Gastroenterology"},{"key":"8456_CR93","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1074-7613(02)00362-X","volume":"17","author":"AV Collins","year":"2002","unstructured":"Collins AV, Brodie DW, Gilbert RJ et al (2002) The interaction properties of costimulatory molecules revisited. Immunity 17:201\u2013210","journal-title":"Immunity"},{"key":"8456_CR94","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1517\/14712598.5.9.1245","volume":"5","author":"GG Teng","year":"2005","unstructured":"Teng GG, Turkiewicz AM, Moreland LW (2005) Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther 5:1245\u20131254","journal-title":"Expert Opin Biol Ther"},{"key":"8456_CR95","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/hep.26067","volume":"57","author":"A Dhirapong","year":"2013","unstructured":"Dhirapong A, Yang GX, Nadler S et al (2013) Therapeutic effect of cytotoxic T lymphocyte antigen 4\/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 57:708\u2013715","journal-title":"Hepatology"},{"key":"8456_CR96","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaut.2014.01.034","volume":"50","author":"W Huang","year":"2014","unstructured":"Huang W, Kachapati K, Adams D et al (2014) Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells. J Autoimmun 50:123\u2013134","journal-title":"J Autoimmun"},{"key":"8456_CR97","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/hep.27230","volume":"60","author":"A Lleo","year":"2014","unstructured":"Lleo A, Zhang W, McDonald WH et al (2014) Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology 60:1314\u20131323","journal-title":"Hepatology"},{"key":"8456_CR98","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/cei.12415","volume":"178","author":"H Tanaka","year":"2014","unstructured":"Tanaka H, Zhang W, Yang GX et al (2014) Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells. Clin Exp Immunol 178:253\u2013261","journal-title":"Clin Exp Immunol"},{"key":"8456_CR99","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.4049\/jimmunol.1301092","volume":"191","author":"J Wang","year":"2013","unstructured":"Wang J, Budamagunta MS, Voss JC et al (2013) Antimitochondrial antibody recognition and structural integrity of the inner lipoyl domain of the E2 subunit of pyruvate dehydrogenase complex. J Immunol 191:2126\u20132133","journal-title":"J Immunol"},{"key":"8456_CR100","doi-asserted-by":"crossref","unstructured":"Wang L, Sun Y, Zhang Z et al. (2014) CXCR5 CD4 T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology, doi: 10.1002\/hep.27306 . [Epub ahead of print]","DOI":"10.1002\/hep.27306"},{"key":"8456_CR101","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/s-0034-1383729","volume":"34","author":"L Wang","year":"2014","unstructured":"Wang L, Wang FS, Chang C, Gershwin ME (2014) Breach of tolerance: primary biliary cirrhosis. Semin Liver Dis 34:297\u2013317","journal-title":"Semin Liver Dis"},{"key":"8456_CR102","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/hep.26979","volume":"59","author":"CY Yang","year":"2014","unstructured":"Yang CY, Ma X, Tsuneyama K et al (2014) IL-12\/Th1 and IL-23\/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology 59:1944\u20131953","journal-title":"Hepatology"},{"key":"8456_CR103","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaut.2014.02.009","volume":"51","author":"Y Yao","year":"2014","unstructured":"Yao Y, Yang W, Yang YQ et al (2014) Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Ralpha(\u2212\/\u2212) mice. J Autoimmun 51:99\u2013108","journal-title":"J Autoimmun"},{"key":"8456_CR104","doi-asserted-by":"crossref","unstructured":"Zhang, J., Zhang, W., Leung, P. S., et al. (2014), Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology doi: 10.1002\/hep.27313 . [Epub ahead of print]","DOI":"10.1002\/hep.27313"},{"key":"8456_CR105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2013.07.003","volume":"46","author":"K Hudspeth","year":"2013","unstructured":"Hudspeth K, Pontarini E, Tentorio P et al (2013) The role of natural killer cells in autoimmune liver disease: a comprehensive review. J Autoimmun 46:55\u201365","journal-title":"J Autoimmun"},{"key":"8456_CR106","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaut.2012.12.007","volume":"41","author":"PS Leung","year":"2013","unstructured":"Leung PS, Wang J, Naiyanetr P et al (2013) Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun 41:79\u201386","journal-title":"J Autoimmun"},{"key":"8456_CR107","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","volume":"8","author":"GM Hirschfield","year":"2013","unstructured":"Hirschfield GM, Gershwin ME (2013) The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 8:303\u2013330","journal-title":"Annu Rev Pathol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-014-8456-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-014-8456-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-014-8456-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T03:15:20Z","timestamp":1717470920000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-014-8456-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,21]]},"references-count":107,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["8456"],"URL":"https:\/\/doi.org\/10.1007\/s12016-014-8456-5","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,21]]}}}